EU unveils draft guidance to fast-track clinical trials during public health emergencies

The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations

Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul

Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

Eugia Pharma launches Pomalidomide capsules in US market

Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy

The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Glenmark bags FDA nod for generic asthma inhaler with 180-day exclusivity

Zydus receives final approvals from USFDA for Ivermectin Tablets USP

Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans

Emcure partners with Roche to boost nephrology and transplant care in India

Emcure to distribute Roche's kidney transplant and anemia drugs in India

Alembic Pharma secures USFDA approval for generic Lamotrigine orally disintegrating tablets

The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder